This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dressman, H. K. Articles by Blackwell, K. Search for Related Content PubMed PubMed Citation Articles by Dressman, H. K. Articles by Blackwell, K.

Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy

Authors' Affiliations: ¹ Duke Institute for Genome Sciences and Policy, Departments of ² Molecular Genetics and Microbiology, ³ Surgery, ⁴ Radiation Oncology, and ⁵ Medicine, Duke University Medical Center, ⁶ Institute of Statistics and Decision Sciences, Duke University, Durham, North Carolina

Requests for reprints: Holly Dressman, Duke Inst. for Genome Sciences & Policy, Box 3382, Durham, NC 27710. Phone: 919-668-1583; Fax: 919-681-8973; E-mail: dress002{at}mc.duke.edu.

Purpose: Breast cancer is a heterogeneous disease, and markers for disease subtypes and therapy response remain poorly defined. For that reason, we employed a prospective neoadjuvant study in locally advanced breast cancer to identify molecular signatures of gene expression correlating with known prognostic clinical phenotypes, such as inflammatory breast cancer or the presence of hypoxia. In addition, we defined molecular signatures that correlate with response to neoadjuvant chemotherapy.

Experimental Design: Tissue was collected under ultrasound guidance from patients with stage IIB/III breast cancer before four cycles of neoadjuvant liposomal doxorubicin paclitaxel chemotherapy combined with local whole breast hyperthermia. Gene expression analysis was done using Affymetrix U133 Plus 2.0 GeneChip arrays.

Results: Gene expression patterns were identified that defined the phenotypes of inflammatory breast cancer as well as tumor hypoxia. In addition, molecular signatures were identified that predicted the persistence of malignancy in the axillary lymph nodes after neoadjuvant chemotherapy. This persistent lymph node signature significantly correlated with disease-free survival in two separate large populations of breast cancer patients.

Conclusions: Gene expression signatures have the capacity to identify clinically significant features of breast cancer and can predict which individual patients are likely to be resistant to neoadjuvant therapy, thus providing the opportunity to guide treatment decisions.

This article has been cited by other articles:

				J. D. Minna, L. Girard, and Y. Xie Tumor mRNA Expression Profiles Predict Responses to Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4329 - 4336. [Full Text] [PDF]

				P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug Breast cancer prognostication and prediction in the postgenomic era Ann. Onc., August 1, 2007; 18(8): 1293 - 1306. [Abstract] [Full Text] [PDF]

				F. Peintinger, K. Anderson, C. Mazouni, H. M. Kuerer, C. Hatzis, F. Lin, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4078 - 4082. [Abstract] [Full Text] [PDF]

				S. C. Winter, F. M. Buffa, P. Silva, C. Miller, H. R. Valentine, H. Turley, K. A. Shah, G. J. Cox, R. J. Corbridge, J. J. Homer, et al. Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers Cancer Res., April 1, 2007; 67(7): 3441 - 3449. [Abstract] [Full Text] [PDF]

				F. Huang, K. Reeves, X. Han, C. Fairchild, S. Platero, T. W. Wong, F. Lee, P. Shaw, and E. Clark Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection Cancer Res., March 1, 2007; 67(5): 2226 - 2238. [Abstract] [Full Text] [PDF]

				E. Dahl, G. Kristiansen, K. Gottlob, I. Klaman, E. Ebner, B. Hinzmann, K. Hermann, C. Pilarsky, M. Durst, M. Klinkhammer-Schalke, et al. Molecular Profiling of Laser-Microdissected Matched Tumor and Normal Breast Tissue Identifies Karyopherin {alpha}2 as a Potential Novel Prognostic Marker in Breast Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 3950 - 3960. [Abstract] [Full Text] [PDF]